🩹 Naloxone Co-Prescribing Policy Simulator

Opioid Prescription Written

Every naloxone co-prescribing pathway begins with an ordinary clinical event: a patient is prescribed an opioid for acute pain (a wisdom-tooth extraction, a surgery, a fracture) or for chronic pain management. At the moment the prescription is written, the opioid itself is the only medication in play — naloxone has not yet entered the picture.

• ~125M: US opioid prescriptions/yr (dispensed at retail pharmacies)
• 5–8M: Chronic opioid therapy patients (US, long-term use)
• ≥50 MME/day: Common co-Rx trigger threshold (used by many state policies)
• ~80,000: Opioid overdose deaths/yr (US) (CDC provisional estimate)

What "co-prescribing" means

Naloxone co-prescribing is the practice of writing a naloxone prescription alongside — not instead of — an opioid prescription, at the same visit, whenever the patient carries meaningful overdose risk. The naloxone is not for the clinician or the pharmacy to hold onto: it goes home with the patient (or their household) so that if an overdose occurs, a reversal agent is already in the medicine cabinet rather than minutes away in an ambulance.

This is a deliberately proactive model. Rather than waiting for an overdose to happen and then dispatching emergency medical services (EMS), co-prescribing treats the opioid prescription itself as the trigger for stocking a rescue medication — before anything has gone wrong.

Acute versus chronic prescribing context

The simulation treats every incoming prescription the same way, but in practice the underlying context varies widely:

• Acute, short-course prescriptions (post-surgical, dental, injury-related) typically involve lower total exposure and lower MME, but still carry risk — particularly for opioid-naive patients or when combined with other sedatives during recovery.

• Chronic opioid therapy for long-term pain management involves sustained, often escalating daily dosing, tolerance development, and a materially higher cumulative overdose risk over months and years — especially when a second sedating medication (like a benzodiazepine) is also being managed for the same patient.

Both pathways feed into the same screening checkpoint in this simulator: what matters for co-prescribing eligibility is the risk profile at the time the prescription is written, not merely whether the use is acute or chronic.

Why pair the antidote with the drug that creates the risk

Opioids are respiratory depressants: at sufficiently high blood concentrations — whether from the prescribed dose, an accidental double-dose, interaction with alcohol or benzodiazepines, or diversion to another household member — they can slow or stop breathing. Naloxone is a fast-acting opioid antagonist that can reverse this effect within minutes when administered promptly.

The logic of co-prescribing is simple: the same clinical encounter that creates the overdose risk is the most reliable, lowest-friction moment to also arm the household against it. Waiting for a separate pharmacy visit, a different prescriber, or a public health outreach program to supply naloxone later introduces drop-off at every additional step.

Risk Factor Screening — Dose, Benzodiazepines, History, OUD

Before a co-prescribing decision can be made, the prescription passes through a screening checkpoint. Four factors are evaluated: the daily morphine milligram equivalent (MME) dose, whether the patient is concurrently taking a benzodiazepine, whether they have a documented prior overdose, and whether they carry an opioid use disorder (OUD) diagnosis.

• ≥50 MME/day: CDC caution threshold (reassess risk vs benefit)
• ≥90 MME/day: CDC high-risk threshold (avoid or justify carefully)
• ~15–20%: Chronic patients also on benzos (concurrent prescribing)
• 2–4×: Overdose risk with benzo + opioid (higher than opioid alone)

Calculating morphine milligram equivalents (MME)

Opioids differ enormously in potency — 1 mg of hydromorphone is not equivalent to 1 mg of codeine. To compare risk across different drugs and formulations on a common scale, clinicians convert every opioid to its morphine milligram equivalent (MME): each drug has a published conversion factor, multiplied by the daily dose, and summed if a patient is on more than one opioid.

MME is the backbone of most co-prescribing policy, because overdose risk rises steeply — not just linearly — as daily MME increases. A patient on 20 MME/day is in a fundamentally different risk category than one on 100 MME/day, and screening tools use MME as the primary quantitative input into the risk score.

Risk-factor stacking: multiplicative, not additive

A core insight behind modern co-prescribing guidance is that risk factors do not simply add together — they compound. A high MME dose alone is concerning; a high MME dose plus a concurrent benzodiazepine is substantially more dangerous, because both drug classes depress the central nervous system and respiration through overlapping pathways.

In this simulator, the underlying risk score is modeled multiplicatively: dose sets the baseline, and each additional factor — benzodiazepine co-use, prior overdose history, OUD diagnosis — multiplies that baseline upward rather than adding a fixed increment. This mirrors real clinical reasoning: a patient with prior overdose history at a moderate MME dose may be flagged as high-risk even though their raw dose alone would not have crossed the threshold.

A single prior overdose is one of the single strongest predictors of a future fatal overdose — stronger, in isolation, than dose alone. That is why history stacks so heavily in the risk calculation.

Screening tools and clinical decision support

In real health systems, this screening step is increasingly automated: electronic health record (EHR) systems calculate MME automatically from the prescribed drug, dose, and frequency, cross-reference the state prescription drug monitoring program (PDMP) for concurrent benzodiazepine prescriptions from other prescribers, and flag prior overdose or OUD diagnoses already in the chart.

When the combined score crosses a configured threshold, the EHR fires a clinical decision support alert at the point of prescribing — reminding the clinician to consider (or, in some systems, requiring them to document a reason for not offering) a naloxone co-prescription before the opioid order can be finalized.

Co-Prescribing Threshold Decision

Once a prescription is flagged as high-risk, whether naloxone actually gets co-prescribed depends on two separate things: whether the risk score crosses the policy's defined threshold, and whether the clinician follows through on offering it in that specific encounter. Both vary substantially across states, health systems, and individual prescribers.

• 46+: States with naloxone access laws (some form of expanded access)
• ~15: States mandating/strongly urging co-Rx (at a defined MME threshold)
• <5%: Pre-policy co-prescribing rate (among eligible patients nationally)
• 40–60%: Best-performing health systems (co-prescribing rate post-policy + EHR alert)

State-level laws and guideline variability

Naloxone co-prescribing policy in the United States is a patchwork rather than a single national standard. Many states have passed laws that require or strongly recommend prescribers offer naloxone whenever a patient's daily dose reaches a defined MME threshold (commonly somewhere between 50 and 90 MME/day), or whenever specific risk factors like concurrent benzodiazepine use or a documented prior overdose are present.

Other states rely on professional society guidelines (e.g., from state medical boards or specialty societies) rather than binding statute, and enforcement or auditing of adherence is inconsistent. The result is that two patients with an identical risk profile can have very different odds of leaving the pharmacy with a naloxone kit, purely based on which state, health system, or individual prescriber they encounter.

How the decision point actually fires

In this simulator's "gate," a prescription that was flagged eligible during screening does not automatically become co-prescribed — it passes through a second checkpoint governed by the Clinician Adherence slider. This models the real-world gap between a policy existing on paper and a clinician actually acting on it in a specific, often time-pressured encounter.

Adherence is shaped by workflow friction (does the EHR interrupt the order with an actionable alert, or a silent chart flag that's easy to miss?), by clinician familiarity and comfort discussing overdose risk with the patient, and by whether the pharmacy will fill the naloxone prescription without extra hurdles.

Overcoming stigma in the conversation

A recurring real-world barrier to co-prescribing is not clinical uncertainty but interpersonal discomfort: some clinicians worry that offering naloxone will feel accusatory or alarming to a patient who does not see themselves as at risk of "overdosing." Framing matters enormously here.

Guidelines increasingly recommend a normalized, universal-precautions framing — offering naloxone the same way a smoke detector is installed in every home, regardless of whether that particular household has ever had a fire. Patients report far less resistance to accepting a naloxone kit when it is presented as standard practice for anyone on this class and dose of medication, rather than as a signal that the clinician suspects misuse.

Household Naloxone Availability

Once co-prescribed and dispensed, naloxone sits in the household — often in a kitchen drawer, medicine cabinet, or bedside table — for weeks, months, or years, doing nothing until the moment it is needed. This standing availability, not any single prescribing event, is the actual safety mechanism co-prescribing policy is trying to build.

• Millions: Naloxone kits distributed/yr (US) (community + pharmacy channels combined)
• 2–3 yrs: Nasal spray shelf life (requires periodic replacement)
• Majority: Overdose reversals by bystanders (not first administered by EMS/clinicians)
• >70%: Household coverage, high-adherence systems (of eligible high-risk patients)

The "smoke detector" model of harm reduction

The framing that has done the most to shift naloxone co-prescribing from a stigmatized, opt-in special case toward routine standard of care is the smoke detector analogy: nobody installs a smoke detector because they expect a fire — they install it because fires are possible, rare as they may be, and being unprepared when one happens is far worse than the minor cost of preparation.

Household naloxone availability works the same way. It sits unused in the vast majority of prescriptions, exactly like most smoke detectors never sound an alarm — but for the fraction of households where an overdose event occurs, its presence is often the difference between a reversible event and a fatal one.

Beyond the patient — bystander administration

A critical, often underappreciated feature of household naloxone: the person who administers it during an overdose is usually not the patient themselves (who is, by definition, incapacitated during an overdose) but a family member, partner, roommate, or other bystander who happens to be present.

This means household-level availability protects more than the named patient on the prescription — it protects everyone who shares that household, including in scenarios of diversion (the prescribed opioid being taken, with or without permission, by someone other than the patient) or a household member's own separate substance use. The co-prescribing decision, in effect, arms an entire household, not just an individual.

Barriers to real-world uptake despite prescription

A written co-prescription does not guarantee a naloxone kit actually ends up in the home. Gaps occur at several downstream points: the pharmacy may not stock naloxone or may require a separate transaction with its own copay; patients may decline to fill the naloxone prescription due to cost, stigma, or simply not registering it as important compared to the pain medication they came for; and even filled kits can expire unnoticed if not periodically checked and replaced.

Health systems that achieve high real-world household coverage typically combine the prescription itself with active dispensing support — co-locating naloxone at the same pharmacy counter, waiving or minimizing copays, and following up to confirm the kit was actually picked up.

Overdose Event Outcome Comparison

The entire policy chain — screening, threshold, co-prescribing, household availability — exists to change what happens in the seconds and minutes after an overdose begins. This final stage compares simulated outcomes for households with a naloxone kit already on hand versus households relying solely on a delayed emergency response.

• >90%: Reversal rate, prompt naloxone (when administered quickly by bystander)
• 8–12 min: Typical EMS response time (urban/suburban median, longer rural)
• Well under 50%: Real-world co-Rx adherence gap (of guideline-eligible patients in many systems)
• Substantial: Modeled lives saved, wide access (per published population-level modeling studies)

Simulated outcome comparison, side by side

In the live simulation, overdose events are triggered at random households regardless of whether they have a kit — mirroring the fact that overdoses can originate from the prescribed opioid, a household member's diversion of it, or unrelated escalation. What differs is the resolution path:

Households with a kit present resolve quickly: a bystander recognizes the overdose, administers intranasal naloxone within minutes, and breathing is restored — reflected in the simulation as a fast green resolution.

Households without a kit must instead wait for EMS: someone has to notice the overdose, call emergency services, and wait for arrival — a process that takes materially longer and carries meaningfully lower odds of a successful reversal, reflected as a slower, less certain resolution that is often red.

The gap between the two outcome paths in this simulator is not decoration — it is the entire policy argument for co-prescribing in one comparison: minutes matter, and naloxone that is already in the room outperforms naloxone that has to be dispatched.

The real-world adherence gap

Despite the strength of the underlying case, actual co-prescribing rates among guideline-eligible, high-risk patients remain well below where policy intends them to be in most health systems. Studies examining EHR data across large systems have repeatedly found that even where a clear risk threshold and an active clinical alert exist, a substantial share of eligible encounters still do not result in a naloxone co-prescription.

The Clinician Adherence slider in this simulator is a direct stand-in for this gap: adjusting it from a low, real-world-typical value to a high, best-practice value shows how much of the eventual household coverage and reversal outcome is determined not by the policy's threshold design, but by whether it is actually followed at the point of care.

Naloxone as standard of care, not a stigmatized exception

The broader trajectory of this field has been a shift away from treating naloxone as a specialized intervention reserved for patients clinicians consider "high risk" in a judgmental sense, and toward treating it as a routine companion medication to opioid prescribing generally — much like an EpiPen accompanies a new severe allergy diagnosis, or a smoke detector accompanies a new home, regardless of whether that particular patient or home is ever expected to need it.

As more states codify co-prescribing thresholds into law, as EHR systems make the screening and offer nearly automatic, and as pharmacy-level barriers to dispensing naloxone continue to fall, the practice is moving from a stigmatized special case toward an unremarkable, expected part of opioid prescribing — exactly the direction this simulation's policy sliders are designed to let you explore.